Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis.

about

Low-molecular weight heparin infusion as anticoagulation for haemodialysis.

P2860

Q38835775-5DAA3BBF-052D-4A06-9635-C28297E308A7

P2860

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis.

Item

http://www.wikidata.org/entity/Q40207102

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis.

@en

type

Item

label

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis.

@en

prefLabel

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis.

@en

P1476

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis.

@en

P2093

Arne J Risselada

http://www.w3.org/2001/XMLSchema#string

Edward Buitenwerf

http://www.w3.org/2001/XMLSchema#string

Eric N van Roon

http://www.w3.org/2001/XMLSchema#string

Marc H Hemmelder

http://www.w3.org/2001/XMLSchema#string

Nic J G M Veeger

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Essentials of anticoagulation in hemodialysis.

Review: anticoagulation for haemodialysis.

Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials.

Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.

Low-molecular-weight heparin in patients with renal insufficiency.

The impact of short daily and nocturnal hemodialysis on quality of life, cardiovascular risk and survival.

Thrice-weekly nocturnal hemodialysis: the overlooked alternative to improve patient outcomes.

Hemostasis in renal disease: pathophysiology and management.

Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.

P304

276-279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBACLI.2015.03.006

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274404641

http://www.w3.org/2001/XMLSchema#string

P698

26672512

http://www.w3.org/2001/XMLSchema#string

P932

4661578

http://www.w3.org/2001/XMLSchema#string

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis.

about

P2860

P2860

Effect of nadroparin on anti-Xa activity during nocturnal hemodialysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932